Quantum Genomics

Quantum Genomics announces the appointment of its new Scientific Advisory Board

Professor George L. Bakris (Chicago, US), Professor Gregory Y. H. Lip (Liverpool, UK) and Professor Atul Pathak (Monaco) are joining Prof. Keith C. Ferdinand and Prof. Alexandre Persu on the Committee.

READ THE PRESS RELEASE

Stéphane Cohen joins Quantum Genomics.

Stéphane Cohen, a pharmacist and ESSEC graduate, is joining the team as Director of Global Operations.

READ THE PRESS RELEASE

Quantum Genomics signs an exclusive license and production agreement with Gulf Pharmaceuticals Industries Julphar.

READ THE PRESS RELEASE

Senior Female Scientist Works with High Tech Equipment in a Modern Laboratory. Her Colleagues are Working Beside Her.

Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure

Dr. Catherine Llorens-Cortes will present results of a preclinical study of QGC606 in heart failure after myocardial infarction. The oral presentation will be delivered during the "Late Breaking Basic & Translational Science" sessions of the annual congress of the European Society of Cardiology on August 28th 2021

READ THE PRESS RELEASE

Exclusive interview with Professor Gilles Montalescot

Before the presentation of the results of the QUORUM study on August 27, Prof. Montalescot gives
an update on its interest and on heart failure.

READ THE PRESS RELEASE

Blue double exposure of money coins stacking with bar graph for financial and investment business concept.

Quantum Genomics Secures €3 Million Non-dilutive Financing

Quantum Genomics has obtained a €1.5 million loan guaranteed by the French government (PGE) and granted by BNP bank and a €1.5 million innovation and R&D loan granted by Bpifrance

READ THE PRESS RELEASE

Quantum Genomics Reports Full Year 2020 Operating and Financial Results

Recruitment of first subjects for Phase III trial in difficult-to-treat and resistant arterial hypertension patients
Finalization of recruitment for Phase IIb trial in heart failure with upcoming results expected in 2021
Strong cash position of €27.1 million at December 2020
Licensing agreement activities acceleration in second semester 2020

READ THE PRESS RELEASE

Expanding his empire using technological resources

Orient EuroPharma (OEP) acquires a stake in Quantum Genomics

As a follow-up to the agreement signed last September, OEP acquired a minority stake in the capital of Quantum Genomics, thus strengthening the cooperation between the two companies.

READ THE PRESS RELEASE

Quantum Genomics

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.